Skip to main content
Premium Trial:

Request an Annual Quote

Rob Seitz

Insight Genetics has named Rob Seitz as chief technology officer. As CTO, Seitz will oversee the development and commercialization of Insight's genetic assays for the identification of triple-negative breast cancer using technology licensed out of the Vanderbilt Ingram Cancer Center. Prior to joining Insight, Seitz was senior vice president for technology assessment at Clarient (part of GE Healthcare). He also was co-founder and CEO of Applied Genomics prior to its acquisition by Clarient.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.